Clover Health Investments (NASDAQ:CLOV – Get Free Report) and Strata Skin Sciences (NASDAQ:SSKN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.
Profitability
This table compares Clover Health Investments and Strata Skin Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Clover Health Investments | -3.29% | -16.79% | -9.95% |
| Strata Skin Sciences | -35.64% | -476.73% | -33.49% |
Volatility & Risk
Clover Health Investments has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Strata Skin Sciences has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.
Insider and Institutional Ownership
Valuation & Earnings
This table compares Clover Health Investments and Strata Skin Sciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Clover Health Investments | $1.77 billion | 0.59 | -$43.01 million | ($0.11) | -18.36 |
| Strata Skin Sciences | $33.56 million | 0.06 | -$10.09 million | ($2.67) | -0.13 |
Strata Skin Sciences has lower revenue, but higher earnings than Clover Health Investments. Clover Health Investments is trading at a lower price-to-earnings ratio than Strata Skin Sciences, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and target prices for Clover Health Investments and Strata Skin Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Clover Health Investments | 1 | 3 | 1 | 0 | 2.00 |
| Strata Skin Sciences | 1 | 0 | 1 | 0 | 2.00 |
Clover Health Investments presently has a consensus price target of $3.23, indicating a potential upside of 60.07%. Strata Skin Sciences has a consensus price target of $6.00, indicating a potential upside of 1,639.13%. Given Strata Skin Sciences’ higher possible upside, analysts clearly believe Strata Skin Sciences is more favorable than Clover Health Investments.
Summary
Clover Health Investments beats Strata Skin Sciences on 7 of the 12 factors compared between the two stocks.
About Clover Health Investments
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.
About Strata Skin Sciences
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Receive News & Ratings for Clover Health Investments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clover Health Investments and related companies with MarketBeat.com's FREE daily email newsletter.
